About Regeneron Pharmaceuticals Inc

Regeneron is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to battle a variety of diseases and conditions, including cancer, high cholesterol, inflammatory ailments, and eye diseases. The biotechnology company has a handful of products on the market, including eye disease treatment EYLEA, cholesterol lowering drug Praluent, rare inflammatory disease treatment ARCALYST, rheumatoid arthritis drug Kevzara, and cancer treatment ZALTRAP. Regeneron has more than 15 more candidates in clinical development.

Operations

Regeneron operates in one business segment which includes all activities from discovery and development through commercialization of its pharmaceutical products. It has development candidates in areas including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.

The company collaborates with Bayer on the development and commercialization of EYELEA outside of the US. It collaborates with Sanofi to develop and commercialize Praluent globally; Sanofi is also in charge of the development and commercialization of ZALTRAP. Its partnership with Sanofi also includes efforts to discover and develop antibody-based clinical programs. Another partner is Teva, with which it is developing the fasinumab antibody for osteoarthritic and chronic lower back pain.

Geographic Reach

Regeneron has its corporate and research & development headquarters in New York, and a satellite office in New Jersey. It manufactures bulk drug materials in Renssalaer, New York. Internationally, it is headquartered in Dublin, Ireland, and has a manufacturing facility in Limerick.

Sales and Marketing

Regeneron uses distributors and specialty pharmacies to sell its products directly to health care providers. ARCALYST is sold directly to patients.

The company's largest customers are AmerisourceBergen, McKesson, and Express Scripts. They each account for more than 10% of total gross product revenue.

Financial Performance

Thanks to the launching of five products since 2011, Regeneron has reported strong revenue growth over the last few years. In 2016 revenue increased 18% to $4.9 billion, thanks to higher net product sales and an increase of income from the EYLEA collaboration with Bayer.

Net income, which rose 88% in 2015, increased another 41% to $895.5 million in 2016. That increase was driven by the higher revenue, which offset increases in R&D and selling, general, and administrative expenses.

Cash flow from operations has grown for the past five years. In 2016 it rose 11% to $1.5 billion, due largely to the increase in net income.

Strategy

Regeneron has expanded the applications of its protein-based technology to include the creation of human monoclonal antibodies (laboratory-produced cloned proteins). It has a pipeline of 15 clinical-stage antibodies with programs in eye disease, infectious disease, cancer, pain management, cardiovascular disease, and inflammation.

Regeneron has an antibody development agreement with Sanofi that covers potential treatments for ailments including cancer, rheumatoid arthritis, pain, cholesterol, and allergic conditions.

The company also licenses its human antibody technology out to drug developers, who then use Regeneron's technology in researching their own antibody drugs. Licensing partners include AstraZeneca and Astellas Pharma.

In 2016, Regeneron spent $2.1 billion on R&D expenses, up from $1.6 billion in 2015 and $1.3 billion in 2014.

Company Background

In 2012 Regeneron and Bayer HealthCare converted their 50-50 global profit-share agreement for marketing EYLEA (aflibercept) Injection as a treatment for wet AMD outside the US into a royalty arrangement in Japan, where approval for the treatment is pending authorization. Applications for marketing EYLEA have been submitted by Bayer HealthCare in Europe and other countries. The treatment is also in Phase 3 clinical studies for other indications including diabetic macular edema, myopic choroidal neovascularization, and branch retinal vein occlusion.

ARCALYST (rilonacept) was approved by the FDA in 2008 and subsequently became the company's first market-stage product. Regeneron has built up a small marketing force to promote the product in the US; ARCALYST is manufactured at the company's plant in New York and is distributed through third parties. ARCALYST targets Cryopyrin-Associated Periodic Syndromes (CAPS), a series of diseases caused by genetic mutations including Muckle-Wells Syndrome and Familial Cold Auto-inflammatory Syndrome. The drug is also being tested for the treatment of gout.

The company was founded in New York City in 1988.

- Show Less + Show Full Description

Company News and Press Releases

- Show Less + Show More News and Press Releases

Regeneron Pharmaceuticals Inc

777 Old Saw Mill River Rd Ste 10
Tarrytown, NY 10591-6707
Phone: 1 (914) 847-7000
Fax: 1 (914) 347-5045

Stats

  • Employer Type: Public
  • Stock Symbol: REGN
  • Stock Exchange: NASDAQ
  • President and CEO: Leonard S. Schleifer
  • Chairman: P. Roy Vagelos
  • Chief Scientific Officer; President, Regeneron Laboratories: George D. Yancopoulos
  • 2017 Employees: 6,200

Major Office Locations

  • Tarrytown, NY

Other Locations

  • Rensselaer, NY
  • Sleepy Hollow, NY